CPA-7
CPA7 is a novel Stat3 inhibitor. CPA7 downregulates survivin, Bcl-XL, and Mcl-1. CPA7 induces Apoptosis. CPA7 enhances the radiosensitivity of prostate cancer. CPA7 has anti-cancer effects against prostate cancer[1][2].
Product Specifications
CAS Number
16961-77-6
UNSPSC
12352100
Target
Apoptosis; Bcl-2 Family; STAT; Survivin
Related Pathways
Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=[N-]([Pt+4]([Cl-])([Cl-])([NH3])([NH3])[Cl-])=O
Molecular Formula
Cl3H6N3O2Pt
Molecular Weight
381.51
References & Citations
[1]Sekharam M, et al. CPA7, a novel Stat3 inhibitor radiosensitizes prostate cancer cells. International Journal of Radiation Oncology, Biology, Physics, 2005, 63: S483.|[2]Liang M, et al. CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3. BMC Cancer. 2016 Jul 19;16:504.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcl-xL; Mcl-1; STAT3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470253-500 1x 500 µL
Cytokeratin, LMW (AE-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680253-100 1x 100 µL
Cytokeratin, LMW (AE-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681429-100 1x 100 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401563-500 1x 500 µL
Filaggrin (Keratinocyte Differentiation Marker) (FLG/1563), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471012-100 1x 100 µL
S100B (S100B/1012), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details